$4.46 Billion in Sales Expected for Tenet Healthcare Corp (NYSE:THC) This Quarter

Wall Street brokerages predict that Tenet Healthcare Corp (NYSE:THC) will post sales of $4.46 billion for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Tenet Healthcare’s earnings, with the lowest sales estimate coming in at $4.41 billion and the highest estimate coming in at $4.49 billion. Tenet Healthcare reported sales of $4.49 billion in the same quarter last year, which indicates a negative year over year growth rate of 0.7%. The firm is scheduled to announce its next earnings results on Monday, November 4th.

On average, analysts expect that Tenet Healthcare will report full year sales of $18.27 billion for the current year, with estimates ranging from $18.20 billion to $18.36 billion. For the next financial year, analysts anticipate that the business will post sales of $18.81 billion, with estimates ranging from $18.50 billion to $19.03 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Tenet Healthcare.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Monday, August 5th. The company reported $0.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.12. Tenet Healthcare had a negative net margin of 0.09% and a positive return on equity of 28.95%. The business had revenue of $4.56 billion during the quarter, compared to analysts’ expectations of $4.48 billion. During the same quarter in the prior year, the company posted $0.49 earnings per share. The firm’s revenue was up 1.2% on a year-over-year basis.



Several research analysts recently commented on the stock. Royal Bank of Canada restated a “hold” rating and set a $26.00 target price on shares of Tenet Healthcare in a report on Sunday, August 11th. ValuEngine raised shares of Tenet Healthcare from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. SunTrust Banks set a $24.00 price target on shares of Tenet Healthcare and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Finally, Goldman Sachs Group assumed coverage on shares of Tenet Healthcare in a research report on Wednesday, August 14th. They set a “neutral” rating and a $28.00 price target on the stock. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. Tenet Healthcare has an average rating of “Hold” and an average price target of $28.62.

THC traded up $0.82 during trading hours on Friday, hitting $22.95. 42,278 shares of the company’s stock were exchanged, compared to its average volume of 1,605,495. Tenet Healthcare has a 1-year low of $16.60 and a 1-year high of $31.64. The stock’s 50-day moving average is $22.23 and its two-hundred day moving average is $22.37. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 12.34, a PEG ratio of 0.57 and a beta of 1.62. The company has a quick ratio of 1.06, a current ratio of 1.13 and a debt-to-equity ratio of 19.96.

In other news, Director Edward A. Kangas sold 45,000 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $20.28, for a total value of $912,600.00. Following the transaction, the director now directly owns 47,138 shares of the company’s stock, valued at $955,958.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Glenview Capital Management, L acquired 27,424 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was bought at an average cost of $20.99 per share, for a total transaction of $575,629.76. The disclosure for this purchase can be found here. Insiders have acquired 1,325,843 shares of company stock worth $26,843,529 over the last ninety days. Insiders own 1.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Atria Investments LLC acquired a new position in shares of Tenet Healthcare in the second quarter valued at about $967,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Tenet Healthcare during the second quarter worth about $1,271,000. Bank of New York Mellon Corp grew its stake in Tenet Healthcare by 17.1% during the second quarter. Bank of New York Mellon Corp now owns 1,244,022 shares of the company’s stock worth $25,701,000 after buying an additional 181,741 shares in the last quarter. Marshall Wace North America L.P. grew its stake in Tenet Healthcare by 145.0% during the first quarter. Marshall Wace North America L.P. now owns 119,786 shares of the company’s stock worth $3,454,000 after buying an additional 70,899 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in Tenet Healthcare by 595.9% during the second quarter. First Trust Advisors LP now owns 147,085 shares of the company’s stock worth $3,039,000 after buying an additional 125,950 shares in the last quarter. 99.16% of the stock is currently owned by institutional investors.

About Tenet Healthcare

Tenet Healthcare Corporation operates as a diversified healthcare services company. The company operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.

Read More: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Tenet Healthcare (THC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tenet Healthcare (NYSE:THC)

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.